FibroGen Inc (NASDAQ:FGEN) has received a consensus recommendation of “Buy” from the eleven ratings firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $62.67.
Several research firms have weighed in on FGEN. ValuEngine cut FibroGen from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $62.00 price objective on the stock in a research report on Friday, March 8th. BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Piper Jaffray Companies began coverage on FibroGen in a research report on Friday, April 12th. They set a “neutral” rating and a $65.00 price objective on the stock. Finally, TheStreet upgraded FibroGen from a “d+” rating to a “c-” rating in a research report on Friday, March 29th.
FGEN traded down $0.17 during trading hours on Friday, reaching $42.10. The company’s stock had a trading volume of 12,927 shares, compared to its average volume of 818,491. FibroGen has a 52 week low of $33.51 and a 52 week high of $68.55. The company’s 50-day simple moving average is $38.96. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.09. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of -40.94 and a beta of 1.75.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.15. FibroGen had a negative return on equity of 17.71% and a negative net margin of 44.14%. The business had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $20.44 million. During the same quarter in the prior year, the business earned ($0.50) EPS. The firm’s revenue for the quarter was down 25.1% on a year-over-year basis. Analysts predict that FibroGen will post -0.87 EPS for the current year.
In related news, CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $54.07, for a total value of $2,143,118.52. Following the transaction, the chief executive officer now owns 2,573,308 shares in the company, valued at $139,138,763.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Pat Cotroneo sold 3,201 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $43.12, for a total value of $138,027.12. Following the completion of the transaction, the chief financial officer now owns 250,777 shares in the company, valued at approximately $10,813,504.24. The disclosure for this sale can be found here. Insiders sold 261,701 shares of company stock worth $11,134,588 in the last 90 days. 7.83% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Lindbrook Capital LLC increased its position in shares of FibroGen by 150.0% in the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 300 shares during the period. FTB Advisors Inc. acquired a new stake in FibroGen in the first quarter valued at about $27,000. Manchester Capital Management LLC acquired a new stake in FibroGen in the first quarter valued at about $39,000. Cornerstone Advisors Inc. boosted its stake in FibroGen by 672.8% in the first quarter. Cornerstone Advisors Inc. now owns 796 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 693 shares in the last quarter. Finally, Flinton Capital Management LLC acquired a new stake in FibroGen in the fourth quarter valued at about $44,000. Institutional investors own 66.27% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: What is a put option?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.